Premium
F5‐05‐03: Nps in normal cognition and the risk of developing MCI and dementia in the presence of late‐onset nps
Author(s) -
Leoutsakos Jeannie-Marie S.,
Forrester Sarah N.,
Geda Yonas E.,
Lyketsos Constantine
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.441
Subject(s) - dementia , dysphoria , medicine , depression (economics) , clinical psychology , cognition , population , oncology , psychiatry , psychology , disease , environmental health , anxiety , economics , macroeconomics
2004 and 2011, while residing in Olmsted County, Minnesota. At enrollment, five questions from the Blessed Memory Inventory were asked of each participant, and a 10-point scale was constructed, reflecting the individuals’ concerns about their cognitive function. The SCD score was dichotomized into any versus none subjective cognitive complains. Participants were re-evaluated every 15 months for clinical status. Published criteria for CN, mild cognitive impairment (MCI) and dementia were applied at each visit with the evaluators blinded to previous diagnoses and clinical data. At baseline and each follow-up visit, information was obtained from the Clinical Dementia Rating Scale, Neuropsychiatric Inventory, Functional Activities Scale, as well as cognitive function on a standard neuropsychological battery (memory, attention/concentration, language and visuospatial skills), data on medical comorbidities and APOE genotype. We assessed the relationship between any subjective memory complaints and risk of MCI using Cox proportional hazards models. Results:There were 2,061 CN participants who had data on SCD and had at least one follow-up visit. The median follow-up was 3.9 years and 525 developed MCI. Approximately 79 percent of the sample expressed some concern about their cognition. Among those individuals with no cognitive concerns was 4.73 percent developed MCI compared to 7.32 percent in those with some cognitive concern. After controlling for age, education, sex, ApoE4 carrier status, depression/dysphoria, anxiety, attention, memory, global cognition and medical comorbidities, any cognitive complaint predicted progression to MCI (HR1⁄41.35 (95% CI: 1.05-1.73, p1⁄4 0.018)). Conclusions: SCD predicts clinical progression to MCI in a population-based sample after controlling for relevant contributing factors. The construct of SCD might be useful in selecting individuals for pre-clinical intervention trials.